PROGRAM CO-CHAIRS
Philip Newsome, MBChB, PhD, FRCPE, FMedSci
Director, Roger Williams Institute of Liver Studies
Professor of Hepatology, King’s College London
Honorary Consultant Hepatologist, King’s College Hospital
Director of King’s Health Partners Centre for Translational Medicine
London, United Kingdom
Kim Pfotenhauer, DO, FACOFP, DABOM
Associate Professor
Assistant Dean for Clerkship
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
PROGRAM OVERVIEW
This program aims to address the educational requirements of health care professionals and their clinical teams who care for patients experiencing obesity-related liver complications. Participants will learn to implement clinical guidelines for the screening, early detection, and diagnosis of metabolic disorders such as MASH/MAFLD. Additionally, the program will facilitate the analysis of the most recent clinical findings regarding emerging GLP-1/glucagon receptor co-agonists for managing metabolic diseases, while promoting a multidisciplinary approach to enhance care coordination for patients with liver complications linked to obesity.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the role of glucagon and novel hepatic pathways in metabolic health and the development of metabolic MASH/MAFLD
- Adopt clinical guideline recommendations for screening, early recognition, and diagnosis of metabolic conditions like MASH/MAFLD
- Analyze the latest clinical evidence on emerging GLP-1/glucagon receptor co-agonists for metabolic disease management
- Apply a multidisciplinary team approach to enhance care coordination for patients with obesity-related liver complications
TARGET AUDIENCE
This educational activity is intended for HCPs and their clinical teams involved in the care of patients with obesity-related hepatic complications, such as endocrinologists, general and internal medicine physicians, hepatologists, pharmacists, nurse practitioners, physician assistants, and nurses.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Philip Newsome, MBChB, PhD, FRCPE, FMedSci | Receives speaking fees from Eli Lilly, Echosens, Inventiva Pharma, Ipsen, Novo Nordisk and consulting fees from Akero Therapeutics, Aligos Therapeutics, Boehringer Ingelheim, Forth Therapeutics, Inventiva Pharma, Sagimet Biosciences, Madrigal, Novo Nordisk, Shionogi, UCB and 89 Bio. |
| Kim Pfotenhauer, DO, FACOFP, DABOM | Receives consulting fees from Novo Nordisk, is on an advisory board for Boehringer Ingelheim, and has ownership interest in ROMTech. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- Dominique Barton, BS, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Melissa Carter, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 30, 2026
EXPIRATION DATE: January 30, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
